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The diagnosis of glomerulonephritis flares in systemic lupus
erythematosus (SLE) is usually based on whether the
magnitude of proteinuria has changed. Our study tests two
methods to assess proteinuric change: protein/creatinine
(P/C) ratios of intended 24-h urine collections or that of spot
urine samples. Sixty-four patients with glomerulonephritis
due to SLE followed in the Ohio SLE Study provided
bimonthly paired spot and intended 24-h urine collections.
Completeness of each collection was estimated as the ratio of
the measured creatinine to the expected creatinine based
upon Cockroft–Gault. Intended 24-h urine collections with
measured/expected creatinine ratios between 0.5 and 0.9
(237 samples overall) showed ratios that were not
significantly different from ratios of complete 24-h urine
collections with ratios of 0.9–1.1 (159 samples). To compare
spot and 24 h P/C ratios, we randomly selected pairs of
samples with measured/expected ratios above 0.75.
Consistent with previous studies, spot and 24-h urine P/C
ratios showed good correlation over the range of values as
well as reasonably strong concordance. Over the range of
most SLE glomerulonephritis flares, however, correlation was
present but concordance was poor. Our work suggests that
the use of spot urine P/C ratios will yield more false-positive
and -negative diagnoses of glomerulonephritis flares in
patients with SLE than the ratio in 24-h urines.
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In chronic kidney disease, proteinuria magnitude is the
strongest single predictor of glomerular filtration rate
decrease.1–3 Furthermore, therapy that reduces proteinuria
slows glomerular filtration rate decrease. For example,
glomerular filtration rate decrease is slowed by 1–2 ml/min/
year for each therapy-induced 1.0 g/day reduction in
proteinuria achieved by 4–6 months therapy.3–6 Thus, accurate
assessment of proteinuria trends is important in chronic
kidney disease management.6–8
In systemic lupus erythematosus (SLE) glomerulonephri-
tis (GN), accurately assessing proteinuria change is especially
important. For SLE patients whose baseline proteinuria is
o250 mg/day, proteinuria increases of 1.09–17 orX2 g/day18,19
are regarded as evidence of SLE GN flare, and mandate a
prompt increase in steroid or immunosuppressive therapy.
The gold standard to assess proteinuria change is the
protein content of an accurately collected 24-h urine (24-h
proteinuria).6,20 However, 24-h urine testing is a chore for
the patient, and a nuisance for the physician because for each
collection it must be determined whether it is a complete
24-h collection.6 Random single-void (spot) urine testing was
introduced in an effort to streamline further quantitative
proteinuria assessment. Kidney Disease Outcomes Quality
Initiative guidelines now recommend replacing 24-h urine
testing with the protein/creatinine (P/C) ratio of random
spot urine collections.20 This recommendation is based on
the many studies showing a high correlation coefficient
between spot urine P/C ratios and 24-h proteinuria.7,20–30
However, as we have previously pointed out, the high
correlation coefficients are mainly the mathematical con-
sequences of comparing these variables over a wide range.6
Over more restricted, but clinically relevant ranges (e.g., 24-h
urine P/C ratios 0.5–3.0), inspection of the graphical displays
of the previous reports show only weak agreement between
spot P/C ratio and 24-h proteinuria.8,21,24–26,28–31 However,
the previous reports either did not acknowledge or did not
discuss its clinical significance.
This study is the first to assess the relationship between
spot and 24-h urine P/C ratios when the goal is to assess
proteinuria change over the 24-h proteinuria range of 0.5–3 g/
day, the range of most SLE GN flares.9,11,16,17,32 As we have
discussed previously,6,7 there is evidence that in proteinuric
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chronic kidney disease, spot urine P/C ratio varies over a
severalfold range during any given 24-h period, and the
pattern of variability changes from day to day. Thus, the key
question is whether a spot urine is a large enough sample
from which to reliably estimate moderate changes in 24-h
proteinuria. Our results show that it is not. However, the P/C
ratio of an intended 24-h urine that is X50% complete is a
reliable estimate of 24-h proteinuria. On this basis, we
suggest that a reexamination of the use of spot urine P/C
ratio to monitor SLE GN flare is warranted.
RESULTS
Table 1 shows the baseline demographics of the 64 OSS SLE
GN patients studied herein. The majority are young female
subjects with normal or nearly normal serum creatinine
levels.
Expected 24-h urine creatinine levels (E) were calculated
and compared with the measured creatinine levels (M) to
determine the completeness of a 24 h collection (the M/E
ratio). To evaluate whether body size influenced this
determination, the relationship between M/E and body mass
index was assessed by analysis of variance applicable to
repeated measures, where body mass index was used as the
predictor and M/E as the response, and subjects were used as
a random effect. This analysis showed a statistically
significant (Po0.0001) but weak relationship; the correlation
coefficient between the two variables was 0.39, indicating
that the body mass index explained only 16% of the variation
in the M/E ratio. Thus, M/E ratios outside the range of
0.9–1.1 mostly reflected inaccurate 24-h collections, with high
M/E ratios representing over collections, and low M/E ratios
representing under collections.
To assess if completeness of an intended 24-h urine
collection influenced the P/C ratio of the collection, we first
examined the relationship between M/E ratio and P/C ratio
for all 645 intended 24-h urine collections from the 64-
patient cohort (Figure 1a). Using analysis of variance
applicable to repeated measures where M/E ratio was used
as the predictor and log (24-h P/C ratio) as the response, and
subjects as random effects, no relationship between M/E ratio
and P/C ratio was found (P¼ 0.11).
To examine further the relationships shown in Figure 1a, a
subset analysis was performed comparing the P/C ratios in
each of the following M/E ratio categories: 0.5 too0.75, 0.75
to o0.9, 0.9–1.1, and 41.1 (Figure 1b). M/E ratios of o 0.5
were not assessed because of very few values. To mitigate the
possible confounding effect of overrepresentation by a few
individuals with low M/E ratios but high P/C ratios, only
data from patients contributing to at least two of these M/E
ratio categories were used. This resulted in 544 24-h urine
P/C ratios from 50 patients. No differences were found
among the P/C ratios of the four M/E categories, using
analysis of variance applicable to repeated measures, with
M/E category as a fixed effect and subjects as random effects
(P¼ 0.11). These data suggest that the P/C ratio of an
intended 24-h urine collection with an M/E ratio40.5 is a
reliable estimate of the P/C ratio of a complete 24-h
collection. This analysis also reveals the intraindividual
variability of 24-h collections, with 15 patients contributing
to two M/E ratio categories, 23 patients to three categories,
and 12 patients to four categories.
For the primary comparison of paired spot to 24-h urine
P/C ratio, we chose the pairs in which the M/E ratio of the
intended 24-h urine was X0.75. This was done to increase
the reliability with which the intended 24-h urine P/C ratio
estimated the P/C ratio of a complete 24-h collection. The
Table 1 | Baseline demographic and clinical characteristics of
the SLE GN patients
N Age1 Sex2 Race3 Protein/creatinine1 Serum creatinine1
64 34710 60/4 24/35/5 1.872.4 1.270.7



























Mean±s.d. 1.11 ± 1.23 0.74 ± 0.74 0.66 ± 0.82 0.61 ± 0.95
N= 130
M/E ratio
0.5 to<0.75 0.75 to<0.9 0.9 to 1.1 >1.1
107 159 148
M/E ratio
0.0 0.5 1.0 1.5 2.0
Figure 1 | Intended 24-h urine collections that are greater than
50% complete provide p/c ratios comparable to that of complete
24-h urine collections. (a) The relationship between M/E ratio and
24-h urine P/C ratio for each of the 645 individual 24-h collections of
the OSS patients. These values are shown in relationship to the mean
24-h P/C ratio (horizontal line). No relationship between M/E ratio and
P/C ratio was found. (P¼ 0.11). (b) Individual mean 24-h urine P/C
ratios by M/E ratio group are shown. No differences were found
among the P/C ratios of the four M/E ratio categories (P¼ 0.11).
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mean and median M/E ratio for the M/E ratio category
X0.75 was 1.0270.21 s.d. and 1.00, respectively.
Three statistical approaches were used to compare the spot
P/C ratio to the 24-h urine P/C ratio. First, the agreement
between spot and 24-h urine P/C ratio values was expressed
by the concordance correlation coefficient (CCC).33,34
Analysis of the entire range of 24-h urine P/C ratios
(0.06–6.6) showed a strong correlation typical of that of
previous reports (N¼ 55, r¼ 0.778, Po0.0001), and reason-
ably strong concordance (CCC¼ 0.764, 95% lower con-
fidence boundary¼ 0.661). However, over the P/C ratio
range common to most SLE proteinuric flares (0.5–3.0,
Figure 2a), correlation was present (n¼ 34, r¼ 0.529,
P¼ 0.0013), but concordance was poor (CCC¼ 0.479, 95%
lower confidence boundary¼ 0.269), with a wide array of
spot urine P/C ratios for any given 24-h urine P/C ratio.
For the second analysis, simple linear regression analyses
was performed, using spot P/C ratios as the predictor and
24-h urine P/C ratios as the response, both on natural log
scale. Perfect agreement would show a regression line with a
slope of 1.0 and an intercept of 0.0. These analyses showed,
over the entire range of 24-h urine P/C ratios, a slope of 0.877
(P¼ 0.045, compared to a slope of 1.0). In contrast, for 24-h
urine P/C ratios in the range of 0.5–3, the slope was 0.437,
which was highly significantly different from 1.0 (Po0.0001).
The intercept was 0.018 for the entire range of 24-h urine P/C
ratios (P¼ 0.777), and 0.131 for the data in the ratio range of
0.5–3.0 (P¼ 0.061). These analyses further document the
magnitude of discordance between spot P/C and 24-h urine
P/C ratios, particularly over the 24-h P/C ratio range of
0.5–3, as illustrated in Figure 2a.
The third analysis used an inverse prediction/calibration
model where 24-h urine P/C ratios served as the predictor,
and spot urine P/C ratios as the response, both on natural log
scale. This was used to generate a prediction equation, based
on the spot P/C ratios from the entire range of 24-h urine
P/C ratios, to calibrate (predict) 24-h P/C ratios. The predicted
24-h urine P/C ratios were then compared to the actual 24-h
urine P/C ratios to determine a relative measure of error
(percentage of actual 24-h P/C ratio). The results of this
analysis showed a wide range of relative error, from 26 to
280% of the actual values, and with 23% of the predicted
24-h urine P/C ratios incorrectly predicting the actual values
(above or below) by more than 50%. The four worst error
rates appeared in the actual 24-h urine P/C range of 0.5–3.0
(26, 36, 270, and 280%).
Figure 2b shows a further comparison of the individual
spot and 24-h urine P/C ratios in which, for each collection,
the ratio: (spot urine P/C ratio)/(24-h urine P/C ratio) is
shown in relationship to its 24-h urine P/C ratio. This
analysis included the spot/24-h urine pairs in which the M/E
ratios were 0.5 too0.75, and over the entire range of the 24-h
urine P/C ratios in this study. As shown, the addition of the
cohort with less complete collections did not change the
variability of the relationship between spot and 24-h urine
P/C ratio, again demonstrating that intended 24-h urine
collections with M/E ratios40.5 reliably estimate the P/C
ratio of complete 24-h collections. Also shown is that the
greatest relative variability between spot urine P/C ratio and
24-h urine P/C ratio occurs in the 24-h urine P/C ratio range
below 3.0.
DISCUSSION
This study documents weak agreement between spot urine
P/C ratio and the P/C ratio of a complete or mostly complete
24-h urine over the P/C ratio range of 0.5–3.0, the range
encompassing most SLE proteinuric renal flares. Almost all
previous studies that have examined the relationship between
spot and 24-h urine P/C ratios have also displayed weak
agreement between spot P/C ratio and 24-h proteinuria over
this moderate proteinuria range.21–31 However, these reports
either did not acknowledge or did not discuss the clinical
significance of the poor agreement. We suggest that the weak
agreement occurs because spot urine P/C ratio is an








































Figure 2 | Spot urine P/C ratio is a poor predictor of 24-h urine
P/C ratio particularly if the latter is less than 3.0. (a) The relationship
between 24-h urine P/C ratio and the paired spot urine P/C ratio, in
the 24-h urine P/C ratio range of 0.5–3.0. This analysis involves 24-h
urine collections with M/E ratios X0.75. The association was
significant (r¼ 0.529, P¼ 0.0013), but concordance was weak
(CCC¼ 0.479). (b) The relationship between the ratio (spot urine P/C
ratio/24 h urine P/C ratio) and the 24-h urine P/C ratio. This analysis
includes the cohort with M/E ratios between 0.5 and o0.75 (open
circles) and the cohort with M/E ratios X0.75 (filled circles), over the
entire range of the 24-h urine P/C ratios in this study.
Kidney International (2007) 72, 865–870 867
DJ Birmingham et al.: Spot urines poorly estimate 24-h proteinuria o r i g i n a l a r t i c l e
P/C ratio of a 24 h collection that is 50% or more complete is
a reliable estimate of 24-h proteinuria. The evidence for these
interpretations is as follows:
First, the P/C ratio of a complete 24-h urine collection
conveys essentially the same information as the protein
content of a complete 24-h urine collection. This is the
consequence of the relative constancy of 24-h urine creatinine
excretion. For example, validated 24-h urine collections show
a coefficient of variation for measurements of creatinine
excretion of 4–8%.35 Thus, in a given individual, the P/C
ratio of a complete 24-h collection can be viewed as the 24-h
protein content of that collection divided by a constant.
Second, the method of estimating the completeness of the
24-h urine collection as the M/E ratio is validated by previous
studies showing that the Cockroft–Gault estimate of 24-h
creatinine excretion is highly correlated with directly
measured 24-h urine creatinine excretion (25). Exceptions
to this rule include obese patients or those who have muscle
wasting, where the M/E ratio will not reflect completeness of
the collection (6). These factors did not influence the results
or conclusions of this study.
Third, P/C ratios determined from a large pool of
intended 24-h collections that were 50–75% complete (M/
E¼ 0.5–o0.75) were no different from P/C ratios from more
complete collections (Figure 1b), suggesting that a P/C ratio
from 50% collection is a reliable measure of 24-h urine P/C
ratio. This is not unexpected, as the P/C ratio of a 24-h
collection is the integrated mean of the P/C ratios of the
individual voidings that made up the collection. If the
collected voidings represent more than 12 h of a given 24-h
period, the pooled P/C ratio of those voidings should closely
approach the P/C ratio of a complete 24-h collection. This
follows because of the symmetrical shape of the curve of the
diurnal variation in P/C ratio. The trough values occur in the
morning. The peak values occur at midday.7,21 Thus,
collections that capture greater than 12 h of voidings should
contain both trough and peak P/C ratios.
The method of assessing proteinuria rate from spot urine
P/C ratio assumes not only a constant rate of urinary
creatinine excretion, but also a constant rate of urinary
protein excretion. It is this second assumption, that protein
excretion rate is constant, that is invalid. This causes poor
agreement between spot and 24-h urine P/C ratios. The
inherent variability of proteinuria rate is perhaps best shown
in the work by Koopman et al.,36 where spot urines serially
collected over 3 days showed substantial variation in
proteinuria from one collection to the next. Koopman’s
study was especially compelling because it was done on
patients in a strictly controlled environment (three con-
secutive days of strict bed rest, a constant diet, and no
medications) and the ‘spot urines’ were actually 3-h
collections. Using Koopman’s data, we calculated the P/C
ratios from the consecutive 3-h collections of the representa-
tive patients reported in his publication.7 That showed about
a threefold variation in P/C ratio during the 72-h study
period. The variation in P/C ratio was attributed almost
entirely to variation in proteinuria rate. Creatinine excretion
rates were nearly constant.
Further evidence of the inherent variability of spot urine
P/C ratio is the lack of consensus as to the best time to
measure spot urine P/C ratio to estimate 24-h proteinuria.
The optimum time of day has been variously described as
first morning void,20 morning,8,21 or late afternoon.37 It is
possible that spot urines strategically collected over multiple
periods during a given 24-h period could reliably estimate
24-h urine P/C ratio. However, this has not been addressed in
previous studies, or in this study.
The original intent of spot P/C ratio was to devise a simple
method to differentiate those with overt nephrotic-range
proteinuria from those with minimal proteinuria.21 Clearly,
spot urine testing can do this. What spot urine P/C testing
cannot do is reliably assess moderate changes in 24-h
proteinuria. For example, Figures 2a and b shows that for a
24-h urine P/C ratio of about 1.0, the corresponding spot
urine P/C ratios will range from about 0 to 2.5. Thus, it can
be inferred that the use of spot urine P/C ratio testing will
result in an increased rate of both false-positive and false-
negative diagnoses of SLE GN flare, compared with the use of
24-h urine P/C ratio testing.
This study does not assess the extent to which using spot
urine P/C ratio confounds the accurate diagnosis of SLE GN
flare. That would require a substantial undertaking that is
beyond the scope of this study. The purpose of this study is to
document that such an undertaking is warranted.
MATERIALS AND METHODS
Study patients
These are the 64 SLE GN patients followed in the Ohio SLE Study
(OSS) who submitted at least one intended 24-h urine collection.
Eligibility for the OSS renal cohort has been described pre-
viously.15,32,38 In brief it includes past or present major renal
manifestations attributable to SLE, and a kidney biopsy showing
International Society of Nephrology/Society of Renal Pathologists
Class II, III, IV, or V SLE nephropathy. The OSS protocol involves
bimonthly broad clinical testing including a spot and 24-h urine
collection.15 The spot urines are produced during the study clinic
visits, almost all of which take place in the morning. The spot
specimens are stored at 801C for later testing. The 24-h samples
are collected 24–48 h before each OSS visit, and protein and
creatinine concentrations are determined in The Ohio State
University Medical Center clinical laboratories on the day of the
study visit.
This research protocol was approved by the Ohio State
University IRB, and required informed written consent for
participation, and was in adherence to the Declaration of Helsinki
Principles.
Study design
To determine the completeness of each intended 24-h collection, the
(measured creatinine content (M))/(expected creatinine content
(E)) ratio was calculated from Cockroft–Gault, where
E¼ (140age)weight (kg) 0.2 ( 0.85, if female) (6). The age
and weight at each study visit was used. An M/E ratio of 0.90–1.1
was deemed a complete 24-h collection.
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To assess agreement between spot P/C ratios and intended 24-h
P/C ratios, paired spot and 24-h samples were randomly selected
from our electronic database to cover a range of 24-h urine PC ratio,
all with M/E ratiosX0.5 (for rationale see Results), as follows. First,
all the paired spot and 24-h urine collections in which the 24-h urine
P/C ratio was43.0 were selected, yielding 32 specimens from 16
patients. Second, 32 spot/24-h urine pairs were selected from the
cohort with 24-h urine P/C ratios of 1.0 to o3.0, and 32 spot/24-h
urine pairs were selected from the cohort with 24-h urine P/C ratios
of 0 too1.0. Randomness in selection was achieved by selecting the
first paired specimen that was encountered chronologically for each
patient, with the intent of selecting only one paired specimen per
patient. The stored spot urine specimens that corresponded to the
24-h urine specimens identified above were then retrieved. When
this was done, it was discovered that 10 of the 96 selected pairs had
insufficient volume in the spot specimen because of prior testing.
Thus, the final tally of spot/24-h urine pairs consisted of the
following: in the 24-h urine P/C range of 43.0, 26 specimens from
13 patients; in the 24-h urine P/C range of 1.0 to o3.0, 30
specimens from 26 patients; in the 24-h urine P/C range of 0–1.0, 30
specimens from 28 patients.
Analytic studies
Urine protein and creatinine measurements were performed in the
laboratories of The Ohio State University Medical Center. Urine
protein was measured by an automated pyrogallol red method,39
coefficient of variation 3.3% at mean concentration of 71.6 mg/dl.
Urine creatinine was measured by an automated picric acid method,
coefficient of variation 2.8% at mean concentration of 79.0 mg/dl.
Statistical analysis
The specific statistical analyses are presented below in relationship to
the data. The statistical program SAS JMP Version 6.0 (SAS
Institute, Cary, NC, USA) was used.
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